Objective: To compare the neutrophil-to-lymphocyte ratio (NLR), platelet-tolymphocyte ratio (PLR), and platelet indices between women with pre-eclampsia and normotensive pregnant women.
| INTRODUCTION
Hypertensive disorders of pregnancy complicate 5%-11% of all pregnancies, with pre-eclampsia affecting 3%-5% of all gestations.
1 The American College of Obstetricians and Gynecologists' diagnostic criteria for pre-eclampsia are blood pressure elevation greater than or equal to 140/90 mm Hg on two occasions 4 hours apart after 20 weeks of pregnancy, and proteinuria, or new onset of any of the following: thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, cerebral or visual disturbances. 2 Hyperactivation of inflammatory and immunologic responses in pre-eclampsia causes a marked increase in neutrophil count and modulation of neutrophil function toward greater production of superoxide compared with nitric oxide, which results in endothelial damage and dysfunction. [3] [4] [5] Pre-eclampsia is also known to cause platelet activation, manifesting as low platelet count and high mean platelet volume (MPV).
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Few studies have investigated neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet indices such as MPV in pre-eclampsia. Although some studies have suggested a statistically significant increase in NLR in pre-eclampsia, especially among patients with severe cases, 7, 8 Yavuzcan et al. 9 showed that NLR was not significantly elevated in severe pre-eclampsia when compared with healthy nonpregnant patients. 9 Kashanian et al. 10 reported that MPV was significantly elevated in pre-eclampsia, which contrasted with the results of Yavuzcan et al. 9 who concluded that MPV and PLR were not statistically different between patients with severe pre-eclampsia and healthy pregnant and nonpregnant controls.
The aim of the present study was to compare the systemic inflammatory markers NLR and PLR in women with pre-eclampsia and gestational-age-matched healthy controls. The secondary objectives of the study were to determine any association between various platelet indices such as MPV, platelet distribution width (PDW), and plateletcrit (Pct) and pre-eclampsia, and to study the relationship between red cell distribution width (RDW) and pre-eclampsia.
| MATERIALSANDMETHODS
This cross-sectional study was conducted from January to July 2017 in 
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Blood pressure was measured and urine albumin was estimated using a dipstick test and 24-hour urine sample. Venous blood samples were drawn into 2 mL EDTA tubes before starting induction of labor.
Complete blood count was analyzed using an automated hematology analyzer (ABX Micros ES 60; Horiba Medical, Kyoto Japan). The parameters analyzed were hemoglobin, RDW, platelet count, MPV, Pct, and PDW. Differential leucocyte counts were done on peripheral smear. NLR and PLR were calculated after obtaining the absolute values. Samples were also sent for assessment of liver and kidney function. Fundus examination was done in all women.
Mean values and standard deviations were calculated. Distribution of data was analyzed using the unpaired student t test, and one way ANOVA was used to compare the quantitative data between the two groups. Statistical analysis was performed using SPSS version 20.0 (IBM, Armonk, NY, USA) and P<0.05 was considered statistically significant.
F I G U R E 1 Flow of study patients.
Pregnant women aged 18-40 y at 36-40 wk of pregnancy presenting with preeclampsia (n = 70) History, examination, investigations (hemogram, liver and kidney function tests), fundus, urine albumin Venous blood samples collected:
• Complete blood count analyzed: hemoglobin, red cell distribution width, platelet count, mean platelet volume (MPV), plateletcrit, and platelet distribution width
• Differential leucocyte counts done on peripheral smear
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio calculated 3 excluded: HELLP syndrome
Gestational-agematched controls (n = 67)
| RESULTS
The study group enrolled 70 women; three women were excluded from the analysis because they developed HELLP syndrome, leaving 67 women in the study group. Accordingly, 67 gestational-agematched, healthy pregnant women were included as the control group (Fig. 1) .
The mean age of the women with pre-eclampsia was 28.5 ± 5.6 years compared with 27.8 ± 5.5 years in the control group (P>0.05). Mean hemoglobin levels in the study and control groups were 11.1 ± 2.3 g/dL and 12.2 ± 3.1 g/dL, respectively (P>0.005). As expected, systolic and diastolic blood pressures were significantly higher in women with pre-eclampsia compared with controls. A total of 38 women had mild pre-eclampsia, whereas 29 had severe preeclampsia. Baseline values are summarized in Table 1 .
Mean NLR was higher in women with pre-eclampsia compared with women in the control group (6.8 ± 7.6 vs 3.0 ± 0.98; P=0.001).
Values were also significantly higher in patients with pre-eclampsia compared with healthy pregnant controls for PLR (14.18 ± 14.4 vs 9.54 ± 3.6; P=0.012) and MPV (9.45 ± 1.19 vs 9.02 ± 1.1; P=0.029).
Mean platelet count (×10 9 /L) was significantly lower in the study group compared with the control group (188 ± 89.7 vs 200.1 ± 62.36;
P=0.014). RDW in women with pre-eclampsia was 17.14 ± 2.7, whereas it was 16.19 ± 2.0 in the control group (P=0.025). However, no significant differences were observed between the two groups for Pct and PDW (Table 2) .
Hematological parameters were compared between patients with mild (n=38) and severe (n=29) pre-eclampsia; however, the differences were not assessed for statistical significance because the sample size was small. Mean ratios are summarized in Table 3 .
| DISCUSSION
In the present study, both NLR and PLR were significantly higher in the women with pre-eclampsia compared with the normotensive control group. RDW and MPV were also significantly higher in patients with pre-eclampsia, whereas platelet count was significantly lower in these women compared with the control group. No significant differences between the two groups were observed for Pct and PDW.
NLR is easy and inexpensive to measure; it is reproducible and can be used as a marker of subclinical inflammation. These markers have been studied in various diseases such as diabetes mellitus, coronary artery disease, ulcerative colitis, and cancer. 12, 13 It has been suggested that hyperactivation of inflammatory cells and immunologic responses in pre-eclampsia cause inflammatory cytokines and autoantibodies to be released, and higher production of superoxide resulting in endothelial dysfunction. 3, 4, 14 Pre-eclampsia is associated with dysregulation of TH1-and TH2-type inflammatory responses. 15 Yavuzcan et al. 9 found a statistically significant increase in NLR in women with severe pre-eclampsia compared with healthy nonpregnant women; however, the increase was not significant when healthy pregnant women were compared. In contrast, Kurtoglu et al. 7 and Values are given as mean ± SD unless indicated otherwise.
T A B L E 3 Outcome parameters stratified by severity of pre-eclampsia. Serin et al. 8 showed significantly elevated NLR in pre-eclamptic women and women with severe pre-eclampsia, respectively, compared with healthy pregnant women. The NLR findings of the present study support these results.
PLR plays a role in the cytokine-dependent immune response and is known to increase in severe ischemia, end-organ damage, and pre-eclampsia. 16 Pre-eclampsia is characterized by placental hypoxia, increased oxidative stress, and decreased antioxidants and studies have shown an increase in proinflammatory markers.
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The main limitation of the present study is that the significance of the differences in levels between mild and severe pre-eclampsia could not be calculated owing to small sample size.
Platelet activation plays an important role in the pathogenesis of pre-eclampsia and manifests as low platelet count, high MPV, and increased plasma concentration of other platelet factors in preeclampsia. 19 In cases of thrombocytopenia, an intensified platelet activation state most likely occurs before the onset of pre-eclampsia.
This can be used as a screening test for pre-eclampsia. Increase in MPV is representative of an increase in megakaryocyte production in bone marrow, secondary to stress of thrombocytopenia, and depends on the severity of the inflammatory response. In the present study, platelet count was lower and MPV was higher in women with preeclampsia compared with controls. These results were similar to those of Vilchez et al. 20 and Kashanian et al. 10 who also concluded that MPV is raised in pre-eclampsia. However, Altinbas et al. 21 observed that increased MPV is not a significant predictor for severity of preeclampsia in pregnancy.
PDW is a more significant marker of platelet activation than MPV. Several studies have found a significant increase in PDW and plateletcrit in pre-eclampsia and its association with severity of the disease. 22, 23 Contrastingly, in the present study, PDW and Pct were lower in women with pre-eclampsia, although the differences were not statistically significant.
RDW has been associated with hypertension; however, the cause of the increase in RDW levels in pre-eclampsia has not been fully established. It is hypothesized that this is possibly due to inflammation. Inflammation causes an increase in interleukin-6 levels, which impairs iron metabolism and erythrocyte maturation. Kurt et al.
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showed that high RDW levels were associated with both the presence and severity of pre-eclampsia. However, Abdullahi et al. 25 did not observe any association between RDW and the presence or severity of pre-eclampsia. In the present study, RDW was significantly higher among women with pre-eclampsia.
In conclusion, the present study found that NLR, PLR, RDW, and MPV were all higher in women with pre-eclampsia. Platelet count was significantly lower in pre-eclamptic women and, although also lower, the differences in PDW and Pct between pre-eclamptic pregnant women and the control group were not significant. Hence, during prenatal follow up, measurement of NLR and PLR may be useful to predict pre-eclampsia among women and increased risk.
Further multicenter studies with large numbers of patients and prolonged follow-up are required in this population to confirm these findings. 
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